Regulatory challenges of personalized medicine in the real world: are the right patients being treated with CD19-targeting CAR T-cells?

EMBO Mol Med · 2026 · PMC13270044 · PMID 42045678

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Similar observations have been made across products and indications: in patients treated with tisagenlecleucel, for example, CD19-dim B-ALL cases showed a trend toward a higher rate of failure to achieve deep remission (Pillai et al, 2019 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.